A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension
Recruiting
- Conditions
- HypertensionDiabetes Mellitus
- Registration Number
- NCT05970237
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Brief Summary
The purpose of this clinical trial is to evaluate the efficacy and safety of dapagliflozin in patient with type 2 diabetes mellitus and hypertension
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 9000
Inclusion Criteria
- Those diagnosed with type 2 diabetes mellitus accompanied by hypertension who are scheduled to be administrated Trudapa Tab. or Trudapa M SR Tab.
- Those who voluntarily signed a written personal information agreement to participate in this clinical study.
- Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion.
Exclusion Criteria
- Patients with secondary hypertension: Secondary hypertension is not limited to the following diseases; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.)
- Those who have a history of taking dapagliflozin within 4 weeks of baseline (Visit 1)
- Those who are expected to need insulin prescription during the study period
- Pregnant women, breast-feeding women
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Target blood glucose achievement rate 12weeks after administration Target blood pressure control rate 12weeks after administration
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Gachon University Gil Medical Center
🇰🇷Incheon, Namdong-gu, Korea, Republic of